ABSTRACT
INTRODUCTION
During the third trimester of pregnancy, obstetricians use biomarkers for pre-eclampsia (PE) to optimize the timing of delivery, determining those patients in need of immediate induced delivery and those who will benefit from a watch-and-wait approach, despite having, for example, increased blood pressure or premonitory symptoms. The classic biomarkers include blood pressure, quantitative urinary protein, liver enzymes, platelet count and uric acid, but none is well correlated with maternal or fetal adverse outcome 1 .
Prediction of severe PE and HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome in cases of early-onset PE (gestational age < 34 weeks) is relatively well documented. The ratio between the anti-angiogenic soluble fms-like tyrosine kinase-1 (sFlt-1) and the angiogenic placental growth factor (PlGF), in combination with hypertension and proteinuria, predicts severe PE and HELLP syndrome quite well 2, 3 . However, the performance of this ratio is less convincing for the prediction of adverse outcome in cases of late-onset PE (gestational age ≥ 34 weeks) 4 . Therefore, better biomarkers are warranted, particularly for this group. Since PE is characterized by a rise in systemic vascular resistance, we hypothesized that plasma biomarkers of vasoactive peptides known to be expressed in patients with PE could serve this purpose 5 . Atrial natriuretic peptide (ANP), endothelin, arginine vasopressin and adrenomedullin (ADM) are vasoactive peptides which regulate vascular tone as well as fluid excretion in the kidney. Their half-lives, however, are short, and they are unstable ex-vivo. We therefore focused on laboratory assays that detect stable peptide fragments excised during their post-translational processing [6] [7] [8] [9] : midregional pro-ANP (MR-pro-ANP), C-terminal pro-endothelin-1 (CT-pro-ET-1), copeptin and midregional pro-ADM (MR-pro-ADM), respectively. We furthermore measured sFlt-1, PlGF and corin, a transmembrane serine protease which cleaves the pro-ANP into the active hormone ANP 10 . The purpose of this study was to evaluate the performance of these biomarkers in a cohort of pregnant women presenting with symptoms of PE in the third trimester, specifically with respect to the development of severe PE/HELLP syndrome within 1 week and within 2 weeks following biomarker evaluation.
SUBJECTS AND METHODS

Study population
Between August 2014 and January 2016, we enrolled into the study 324 participants (Figure 1 ). The control group included healthy women with uncomplicated pregnancy seen at the midwife clinic. The cases were women in the third trimester of pregnancy attending an obstetric outpatient clinic with suspected PE, i.e. the obstetrician had requested evaluation of classic serological biomarkers because of increased blood pressure, proteinuria, premonitory symptoms or maternal history -specifically, previous PE. Exclusion criteria were: age < 18 years, inability to speak Danish, gestational age < 25 weeks and declining to participate. For controls, additional exclusion criteria were hypertension and proteinuria. Furthermore, cases in which fetal death occurred and those lost to follow-up were excluded.
At enrolment, we recorded maternal age, height, weight, prepregnancy body mass index (BMI), parity, smoking status, previous PE, mode of conception, diabetes status, gestational age and blood pressure, and obtained blood samples. We used the diagnostic criteria of the American College of Obstetricians and Gynecologists to classify women as having essential hypertension (EH), gestational hypertension (GH), moderate PE or severe PE/HELLP 11 (Table 1) . Some participants did not meet these diagnostic criteria and were classified as having subclinical PE. At subsequent visits we measured blood pressure and obtained blood samples. Pregnancy outcome was recorded.
Approval for this study was obtained from the ethics committee, journal No. 1-10-72-358-14, and the Data Protection agency, journal No. 1-16-02-626-14, in accordance with the WMA Declaration of Helsinki.
Blood samples and analysis
From each patient, at each visit, skilled hospital laboratory technicians drew blood samples (4 mL EDTA plasma and 4 mL serum) from the cubital vein. Samples were centrifuged within 2 h and aliquots stored at -80
• C until analysis. Analyses of sFlt-1, PlGF, N-terminal pro-ANP (NT-pro-ANP), copeptin, MR-pro-ADM and CT-pro-ET-1 were all performed, using the KRYP-TOR compact Plus system (ThermoFisher Scientific, Berlin, Germany), by immunoassay based on TRACE (time-resolved amplified cryptate emission) technology. This technology uses two fluorescent labeled antibodies, which form the antigen-antibody complex, and the proximity of the two antibodies results in an amplified and prolonged fluorescent signal which is proportional to the antigen concentration. sFlt-1 and PlGF were analyzed in serum. NT-pro-ANP, Copeptin, MR-pro-ADM and CT-pro-ET-1 were measured in EDTA plasma. Plasma corin was measured, using an ELISA (enzyme-linked immunosorbent assay) kit (Quantikine, R&D Systems, Abingdon, UK), by a trained laboratory technician.
Statistical analysis
The two groups were compared using one-way analysis of variance (Kruskal-Wallis test). A post-hoc Dunns test was applied for pairwise multiple comparisons with the control group. Primary outcomes were development of severe PE/HELLP syndrome within 1 week and within 2 weeks following assessment of biomarkers. Logistic regression models for the prediction of severe PE/HELLP syndrome within 1 week and 2 weeks of the test were fitted to log 10 -transformed marker values. Gestational age and maternal weight at enrolment were also included as covariates. This meant that assessment of marker combinations was made allowing for gestational age and maternal weight. The fitted probability of severe PE/HELLP from the logistic regression was used to determine screening performance within 1 week and within 2 weeks. Each potential marker was assessed individually, then the most promising markers were assessed in combination. For prediction based on individual markers, results from enrolment and subsequent visit(s) showing whether severe PE/HELLP had developed were used. For prediction by combinations of markers, only patients with results for all three biomarkers (CT-pro-ET-1, sFlt-1 and systolic blood pressure) were included. For comparison, we included assessment of the sFlt-1/PlGF ratio.
RESULTS
Of the 215 participants with suspected PE who were included in the analysis, at a mean gestational age of 35 + 4 weeks, 89 were diagnosed with PE/HELLP at enrolment, increasing to 126 at outcome ( Figure 1 ), with the number diagnosed with severe PE/HELLP increasing from 32 at enrolment to 73 at outcome. Within 1 week of enrolment, 15 new cases of PE or HELLP developed, and within 2 weeks, a further nine developed. Patient characteristics at outcome are given in Table 2 , 
Figure 1
Flowchart summarizing study population and categorization, at enrolment and at outcome, according to American College of Obstetricians and Gynecologists, into subclinical pre-eclampsia (PE), essential hypertension (EH), gestational hypertension (GH), moderate PE and severe PE/HELLP. GA, gestational age. according to their diagnosis at that time. According to ANOVA, those with severe PE/HELLP had higher blood pressure, weight and BMI, while their offspring had lower birth weight and z-score. Table 3 presents biomarker levels at enrolment, with participants categorized according to their diagnosis at Table 2 Baseline characteristics at outcome, according to diagnosis at that time, in 215 women referred to an obstetric outpatient clinic with suspected pre-eclampsia (PE) in third trimester and in 94 with normal pregnancy Data are given as median (interquartile range). Kruskal-Wallis test for non-parametric data and post-hoc Dunns test were applied, testing difference against control group. *P < 0.05. **P < 0.01. ***P < 0.001. CT-pro-ET-1, C-terminal pro-endothelin-1; EH, essential hypertension; GA, gestational age at enrolment; GH, gestational hypertension; MR-pro-ADM, midregional pro-adrenomedullin; MR-pro-ANP, midregional pro-atrial natriuretic peptide; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1. that time, showing that the median levels of all biomarkers except MR-pro-ADM differed between the groups, in particular, cases with severe PE/HELLP having the most extreme values.
Considering together the 183 women with subclinical PE, GH, EH or moderate PE at enrolment, we calculated Presented are areas under receiver-operating characteristics curves (AUC) for prediction of development of severe PE/HELLP syndrome within 1 week and 2 weeks following biomarker analysis at enrolment. All available results for individual markers were used; not all women had results for all markers. *1 week after biomarker analysis: women with subclinical PE, EH, GH or moderate PE, n = 168; women with severe PE/HELLP syndrome, n = 15. †2 weeks after biomarker analysis: women with subclinical PE, EH, GH or moderate PE, n = 159; women with severe PE/HELLP syndrome, n = 24. ALT, alanine aminotransferase; BP, blood pressure; CT-pro-ET-1, C-terminal pro-endothelin-1; LDH, lactic dehydrogenase; MR-pro-ADM, midregional pro-adrenomedullin; MR-pro-ANP, midregional pro-atrial natriuretic peptide; PlGF, placental growth factor; sFlt1, soluble fms-like tyrosine kinase-1. the area under the receiver-operating characteristics curve (AUC) for each individual biomarker concerning the prediction of progression to severe PE/HELLP syndrome within 1 week and within 2 weeks (Table 4) . CT-pro-ET-1, sFlt-1, sFlt-1/PlGF ratio, MR-pro-ANP and systolic blood pressure performed equally well, with 1-week AUCs around 0.81 and 2-week AUCs around 0.77, except for systolic blood pressure (AUC, 0.68). The other biomarkers performed less well, with lower AUCs.
For the 167 cases in which all biomarkers were measured, we also assessed AUCs of different combinations of the five biomarkers which performed particularly well on ROC-curve analysis. The combination of CT-pro-ET-1, sFlt-1 and systolic blood pressure performed best, with a 1-week AUC of 0.94 and a 2-week AUC of 0.83 (Figure 2) . Comparison of the ROC curve for the combination of CT-pro-ET-1, sFlt-1 and systolic blood pressure with that of sFlt-1/PlGF ratio showed the performance of the combination to be significantly better than that of the ratio (AUC, 0.94 vs 0.85; P = 0.005) for prediction of severe PE/HELLP within 1 week, while the difference in performance for prediction within 2 weeks was not statistically significant (AUC, 0.83 vs 0.78; P = 0.19). The combination of CT-pro-ET-1 and systolic blood pressure had a 1-week AUC of 0.92 and a 2-week AUC of 0.81 (not shown). The sensitivities for a fixed 10% false-positive rate confirm the ranking of performance of combinations of biomarker in different groups of patients (Table 5 ). Figure 3 includes only the 57 cases with moderate PE at enrolment. In this group, the combination of CT-pro-ET-1, sFlt-1 and systolic blood pressure had a 1-week AUC of 0.91 and a 2-week AUC of 0.86.
DISCUSSION
In our population of pregnant women with a mean gestational age of 35 + 4 weeks, we found that the vasoactive peptide biomarker CT-pro-ET-1 and the angiogenic factor sFlt-1 predict with high performance the development of severe PE/HELLP within 1 week and within 2 weeks. Furthermore, we found that the combination of CT-pro-ET-1, sFlt-1 and systolic blood pressure Presented are sensitivities of combinations of markers, at fixed 10% false-positive rate, for prediction of development of severe PE/ HELLP syndrome within 1 week and 2 weeks following biomarker analysis at enrolment, in mixed group of women with subclinical PE, gestational hypertension, essential hypertension or moderate PE, and in group of women with moderate PE, including only cases in which all biomarkers were measured. CT-pro-ET-1, C-terminal pro-endothelin-1; sBP, systolic blood pressure; sFlt-1, soluble fms-like tyrosine kinase-1.
performs substantially better than does the sFlt-1/PlGF ratio, particularly for prediction within 1 week. It is a strength of the study that we tested the different biomarkers and different combinations of biomarkers in the same population. A limitation is that this was an exploratory study, in which we used the same data both to develop and to test the prediction models. This may have led to positive bias and our results need to be validated using an independent dataset. Another limitation of the study is that we managed most participants in the outpatient clinic. Therefore, blood pressures were not always measured in accordance with guidelines, i.e. they were not always repeated after 4 h. Thus, the validity needs to be evaluated in other populations, in which contributions of risk factors may differ from those in our population, and which may be managed in accordance with different guidelines, with, for example, differences in antihypertensive drug treatment or indications for induction of labor.
Our results support the hypothesis that endothelin-1 plays a role in the pathogenesis of PE 12 . However, the pathophysiological mechanism leading to increased expression of this potent endothelium-derived vasoconstrictor in PE is not clear 5, 13 . Some studies suggest a link between antiangiogenesis and ET-1 upregulation 14 . Thus, infusion of sFlt-1 in pregnant rats results in hypertension and an increased level of pre-pro-ET1 mRNA in the kidney and placenta 15 . Furthermore, sunitinib, a vascular endothelial growth-factor receptor tyrosine kinase inhibitor, increases blood pressure and plasma endothelin-1 levels in cancer patients 16 . Another biomarker included in this study, MR-pro-ANP, has been reported to be increased in the third trimester in PE 5, 17 , and in the first trimester in women who later develop PE 10 . As ANP acts as a vasodilator, this may reflect a compensatory mechanism counteracting the vasoconstriction in PE. It is well documented that endothelin-1, via binding to the endothelin receptor type-A, increases ANP secretion from atrial myocytes 18, 19 and in isolated atria 20 . When comparing our results with those from most publications analyzing the sFlt-1/PlGF ratio, it is important to remember that we studied late-onset PE in a population with a mean gestational age at enrolment of 35 + 4 weeks. This may explain why we found that the performance of sFlt-1 level was similar to or better than that of the sFlt-1/PlGF ratio, which is in contrast to earlier reports showing the ratio to be superior to each marker individually 21 . These results have potential clinical implications. As a rule-in tool, the combination of CT-pro-ET-1, sFlt-1 and systolic blood pressure may identify patients at risk for disease progression, who may then be offered more focused treatment. As a rule-out tool, it may reduce the number of unnecessary admissions, in turn reducing economic costs and patient anxiety.
